Please login to the form below

Not currently logged in
Email:
Password:

polycystic kidney disease

This page shows the latest polycystic kidney disease news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

Otsuka gains European nod for Jinarc extension. The European Commission has approved a label extension for Jinarc (tolvaptan) to include adult patients with CKD stage 4 Autosomal Dominant Polycystic Kidney Disease ... Jinarc is the only drug treatment

Latest news

More from news
Approximately 2 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • Making good practice common practice in rare disease

    However, fatigue scores can’t be explained purely by disease activity and depression. ... 2015 - 88% of people with early-stage autosomal dominant polycystic kidney disease (ADPKD), reported physical symptoms including pain and general malaise.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
11 London

We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...